Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Paclitaxel, and Bevacizumab in Stage IV Melanoma
NCT00255762Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2005
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in melanoma, sponsored by National Cancer Institute. Primary endpoint: Progression free survival at 8 weeks. Started Dec 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00255762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255762.